Covestor LTD Arcus Biosciences, Inc. Transaction History

Covestor LTD

$155 Million
Q2 2024

A detailed history of Covestor LTD transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Covestor LTD holds 7 shares of RCUS stock, worth $116. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 4 75.0%

Holding current value

$116

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$14.59 - $18.48 $43 - $55	3 Added 75.0%	7 $0
Q1 2024 May 10, 2024	SELL	$14.83 - $20.18 $14 - $20	-1 Reduced 20.0%	4 $0
Q3 2023 Nov 13, 2023	SELL	$17.62 - $23.54 $17 - $23	-1 Reduced 16.67%	5 $0
Q4 2022 Feb 13, 2023	SELL	$19.7 - $35.71 $59 - $107	-3 Reduced 33.33%	6 $0
Q3 2022 Nov 14, 2022	SELL	$23.23 - $30.07 $23 - $30	-1 Reduced 10.0%	9 $0
Q2 2022 Aug 10, 2022	SELL	$17.23 - $37.73 $51 - $113	-3 Reduced 23.08%	10 $0
Q1 2022 May 13, 2022	SELL	$28.92 - $41.83 $115 - $167	-4 Reduced 23.53%	13 $0
Q4 2021 Feb 10, 2022	BUY	$31.38 - $48.47 $533 - $823	17 New	17 $1,000

Others Institutions Holding RCUS

# of Institutions

207

Shares Held

48.9M

Call Options Held

173K

Put Options Held

151K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.2B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Covestor LTD, based on Form 13F filings with the SEC.

News

Stay updated on Covestor LTD with notifications on news.

Account